Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Omeros Corporation - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Omeros Corporation - Product Pipeline Review - 2015', provides an overview of the Omeros Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Omeros Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Omeros Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Omeros Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Omeros Corporation's pipeline products Reasons to Buy - Evaluate Omeros Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Omeros Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Omeros Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Omeros Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Omeros Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Omeros Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Omeros Corporation Snapshot 6 Omeros Corporation Overview 6 Key Information 6 Key Facts 6 Omeros Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Omeros Corporation - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Omeros Corporation - Pipeline Products Glance 16 Omeros Corporation - Clinical Stage Pipeline Products 16 Omeros Corporation - Early Stage Pipeline Products 17 Omeros Corporation - Drug Profiles 21 OMS-405 21 OMS-721 22 Monoclonal Antibodies to Antagonize FN14 for Oncology 24 Monoclonal Antibodies to Antagonize FZD10 for Oncology 26 Monoclonal Antibodies to Antagonize Tie2 for Oncology 28 Monoclonal Antibodies to Antagonize VEGFR2 for Oncology 30 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications 32 Monoclonal Antibodies to Inhibit TROP2 for Oncology 34 OMS-527 36 OMS-616 37 OMS-906 38 Small Molecule to Agonize GPR52 for Schizophrenia 39 Small Molecule to Agonize PTH-1R for Osteoporosis 40 Small Molecule to Antagonize GPR101 for Appetite Disorders 41 Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders 42 Small Molecule to Antagonize GPR139 for Motor Control 43 Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy 44 Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord 45 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders 46 Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia 47 Small Molecule to Antagonize GPR182 for Pancreatic Cancer 48 Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer 49 Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia 50 Small Molecule to Antagonize GPR27 for Obesity and Schizophrenia 51 Small Molecule to Antagonize GPR31 for Anxiety Disorders 52 Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes 53 Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia 54 Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia 55 Small Molecule to Antagonize GPR87 for Cancer 56 Small Molecule to Antagonize NMUR2 for Pain 57 Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders 58 Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia 59 Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders 60 Small Molecule to Target GPR132 for Atherosclerosis 61 Small Molecule to Target GPR141 for Respiratory and Immune Disorders 62 Small Molecule to Target GPR150 for Ovarian Cancer 63 Small Molecule to Target GPR151 for CNS Diseases 64 Small Molecule to Target GPR153 for Schizophrenia 65 Small Molecule to Target GPR162 for Neuropsychiatric Disorders 66 Small Molecule to Target GPR171 for Eating and Hematological Disorders 67 Small Molecule to Target GPR174 for Melanoma and Grave's Disease 68 Small Molecule to Target GPR176 for Atherosclerosis 69 Small Molecule to Target GPR183 for Humoral Immunity 70 Small Molecule to Target GPR21 for Obesity and Diabetes 71 Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis 72 Small Molecule to Target GPR25 for Arterial Stiffness 73 Small Molecule to Target GPR37 for Parkinson's Disease 74 Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy 75 Small Molecule to Target GPR50 for CNS and Metabolic Disorders 76 Small Molecule to Target GPR63 for Autism 77 Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders 78 Small Molecule to Target GPR80 for Hepatocellular Carcinoma 79 Small Molecule to Target GPR82 for Appetite Disorders and Body Weight 80 Small Molecule to Target GPR83 for CNS and Immunological Disorders 81 Small Molecule to Target LGR4 for Cancer and Osteoporosis 82 Small Molecule to Target LGR5 for Esophageal Adenocarcinoma 83 Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles 84 Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer 85 Small Molecule to Target MRGE for Pain 86 Small Molecule to Target MRGF for Pain 87 Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis 88 Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis 89 Omeros Corporation - Pipeline Analysis 90 Omeros Corporation - Pipeline Products by Target 90 Omeros Corporation - Pipeline Products by Route of Administration 92 Omeros Corporation - Pipeline Products by Molecule Type 93 Omeros Corporation - Pipeline Products by Mechanism of Action 94 Omeros Corporation - Recent Pipeline Updates 96 Omeros Corporation - Dormant Projects 101 Omeros Corporation - Discontinued Pipeline Products 102 Discontinued Pipeline Product Profiles 102 Omeros Corporation - Locations And Subsidiaries 103 Head Office 103 Appendix 104 Methodology 104 Coverage 104 Secondary Research 104 Primary Research 104 Expert Panel Validation 104 Contact Us 104 Disclaimer 105
List of Tables
Omeros Corporation, Key Information 10 Omeros Corporation, Key Facts 10 Omeros Corporation - Pipeline by Indication, 2015 12 Omeros Corporation - Pipeline by Stage of Development, 2015 18 Omeros Corporation - Monotherapy Products in Pipeline, 2015 19 Omeros Corporation - Phase II, 2015 20 Omeros Corporation - Preclinical, 2015 21 Omeros Corporation - Discovery, 2015 24 Omeros Corporation - Pipeline by Target, 2015 94 Omeros Corporation - Pipeline by Route of Administration, 2015 96 Omeros Corporation - Pipeline by Molecule Type, 2015 97 Omeros Corporation - Pipeline Products by Mechanism of Action, 2015 98 Omeros Corporation - Recent Pipeline Updates, 2015 100 Omeros Corporation - Dormant Developmental Projects,2015 105 Omeros Corporation - Discontinued Pipeline Products, 2015 106
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
